Previous Close | 9.26 |
Open | 9.33 |
Bid | 9.67 x 1200 |
Ask | 9.83 x 900 |
Day's Range | 9.25 - 9.69 |
52 Week Range | 7.43 - 32.32 |
Volume | 222,026 |
Avg. Volume | 517,449 |
Market Cap | 492.611M |
Beta (3Y Monthly) | 2.26 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.58 |
Earnings Date | Feb 24, 2020 - Feb 28, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.10 |
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
NEW YORK, / ACCESSWIRE / November 13, 2019 / Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ:MGNX). Such investors ...
NEW YORK, NY / ACCESSWIRE / November 12, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. ...
LOS ANGELES, CA / ACCESSWIRE / November 12, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" ...
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. The lawsuit alleges MacroGenics, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (a) the Company had conducted the progression-free survival (“PFS”) and first interim overall survival (“OS”) analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. (“MacroGenics” or “the Company”) (NASDAQ: MGNX) for violations of securities laws. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
NEW YORK , Nov. 12, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" ...
NEW YORK, Nov. 12, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
New York, New York--(Newsfile Corp. - November 12, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MacroGenics, Inc. (NASDAQ: MGNX) ("MacroGenics" or the "Company") of the November 12, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi LogoIf you invested in MacroGenics stock or options between February 6, 2019 and June ...
Q3 2019 MacroGenics Inc Earnings Call
SAN FRANCISCO, CA / ACCESSWIRE / November 12, 2019 / Hagens Berman alerts MacroGenics (NASDAQ:MGNX) investors of today's lead plaintiff deadline to move for lead plaintiff in a federal securities class ...
NEW YORK, NY / ACCESSWIRE / November 11, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine ...
New York, New York--(Newsfile Corp. - November 11, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MacroGenics, Inc. (NASDAQ: MGNX) ("MacroGenics" or the "Company") of the November 12, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi Logo If you invested in MacroGenics stock or options between February 6, 2019 ...
LOS ANGELES, CA / ACCESSWIRE / November 11, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" ...
NEW YORK, NY / ACCESSWIRE / November 11, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered ...
NEW YORK, NY / ACCESSWIRE / November 11, 2019 / Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a motion for lead plaintiff in a securities ...
NEW YORK, Nov. 11, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
SAN FRANCISCO, CA / ACCESSWIRE / November 11, 2019 / Hagens Berman urges MacroGenics (NASDAQ:MGNX) investors who have suffered losses in excess of $50,000 to submit their losses now to learn if they qualify ...
Hagens Berman urges MacroGenics (MGNX) investors who have suffered losses in excess of $50,000 to submit their losses now to learn if they qualify to recover their investment losses. Only two days remain until the November 12, 2019 lead plaintiff deadline in a securities fraud class action pending against the company.
NEW YORK, NY / ACCESSWIRE / November 10, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. A class action has commenced on behalf of certain shareholders in MacroGenics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had conducted the progression-free survival ("PFS") and first interim overall survival ("OS") analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.
AN FRANCISCO, CA / ACCESSWIRE / Novemver 9, 2019 / Hagens Berman urges MacroGenics (NASDAQ:MGNX) investors who have suffered losses in excess of $50,000 to submit their losses now to learn if they qualify ...
NEW YORK, Nov. 09, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MacroGenics, Inc. (NASDAQ: MGNX) from February 6, 2019.
SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2019 / Hagens Berman urges MacroGenics (NASDAQ:MGNX) investors who have suffered losses in excess of $50,000 to submit their losses now to learn if they qualify ...